West has entered an agreement with Janssen Biotech for the development and manufacture of a new self-injection product. The technology, developed by Janssen, has been designed to facilitate easier self-injection of pharmaceutical and biologic drug products. West will market the new injection technology under the name SelfDose and will be responsible for co-development, commercial scale-up, and manufacture of the product.
“We are delighted to have formalized our relationship with Janssen Biotech around this drug delivery platform and look forward to working together to commercialize the SelfDose injection technology, providing manufacturing, development and regulatory support through the remainder of the process,” said Donald E. Morel, Jr., Ph.D., West's chairman and chief executive officer. “We value the opportunity to strengthen our long-standing relationship and are excited by this agreement. We look forward to working with Janssen to help them meet their business goals to restore health and serve patients.”